Profil
Benjamin Fryer is the founder and current Chief Executive Officer of Pluristyx, Inc. which is founded in 2018.
Aktive Positionen von Benjamin Fryer
| Unternehmen | Position | Beginn |
|---|---|---|
Pluristyx, Inc.
 Pluristyx, Inc. BiotechnologyHealth Technology Pluristyx, Inc. is a privately held biotechnology company that helps industry and academic researchers solve manufacturing and analytical challenges in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The company is based in Seattle, WA and has subsidiaries in United States and Canada. The company has decades of experience supporting every stage of cell therapy product development, from cell banking to drug product manufacturing including analytical testing and release of clinical grade cell therapy products. Pluristyx offers consulting, wet-lab services, and pluripotent stem cell products to support novel therapeutic developers. The company was founded in 2018 by Kaye Reiter, Benjamin Fryer, Jason Carstens. Benjamin Fryer has been the CEO since 2018. | Vorstandsvorsitzender | 01.01.2018 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Pluristyx, Inc.
Pluristyx, Inc. BiotechnologyHealth Technology Pluristyx, Inc. is a privately held biotechnology company that helps industry and academic researchers solve manufacturing and analytical challenges in cryopreservation, drug development, regenerative medicine, and cell and gene therapy. The company is based in Seattle, WA and has subsidiaries in United States and Canada. The company has decades of experience supporting every stage of cell therapy product development, from cell banking to drug product manufacturing including analytical testing and release of clinical grade cell therapy products. Pluristyx offers consulting, wet-lab services, and pluripotent stem cell products to support novel therapeutic developers. The company was founded in 2018 by Kaye Reiter, Benjamin Fryer, Jason Carstens. Benjamin Fryer has been the CEO since 2018. | Health Technology |
